We quantified vital clinical feature associations with SIGLEC15 mRNA expression in THCA, and stage, lymph node metastasis (N stage), extrathyroid extension, and BRAF V600E status were found to be positively correlated with SIGLEC15 mRNA expression levels; other clinical factors (e.g., age, gender, residual tumor) indicated no significant relationship with SIGLEC15 mRNA expression (Figures 7A–I). This evidence concerns the gene SIGLEC15 and metastatic malignant neoplasm in the lymph nodes.